Skandinaviska Enskilda Banken (SEB)’s Cidara Therapeutics CDTX Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-15,000	Closed	-$3.31M	–	259
2025 Q4	$3.31M	Buy	+15,000	New	+$2.42M	0.01%	488

Skandinaviska Enskilda Banken (SEB)'s CDTX Position: Q1 2026 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 15,000 shares — an estimated $3.31M sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in CDTX in Q4 2025 and held it in 1 quarter. The position peaked at $3.31M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Skandinaviska Enskilda Banken (SEB) reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Skandinaviska Enskilda Banken (SEB) sold 15,000 Cidara Therapeutics shares in Q1 2026, an estimated $3.31M.
Skandinaviska Enskilda Banken (SEB) first reported a position in Cidara Therapeutics in Q4 2025 and held it in 1 quarter.
Skandinaviska Enskilda Banken (SEB)'s Cidara Therapeutics position peaked at $3.31M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q1 2026, filed 15 May 2026.